|9.11|| -0.04 / -0.44%|
Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a pharmaceutical company developing therapeutics that addresses unmet medical needs in women's health. The company is leveraging its in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities to advance an internal development pipeline, while also providing valuable consultative services to its pharmaceutical industry customers. Its pipeline development is funded by cash flows from its CRINONE franchise and services business. Juniper is currently developing COL-1077, a 10% lidocaine bioadhesive gel intended as an acute use anesthetic for minimally invasive gynecological procedures. Future pipeline products will utilize Juniper's novel drug delivery technologies including its bioadhesive delivery system (BDS) and a segmented intra-vaginal ring (IVR) technology. Juniper intends to advance product candidates through Phase II proof-of-concept and will look to partner for later stage clinical trials and commercialization. The Company has developed and brought to market five bioadhesive gel products, each commercialized through alliances. These include CRINONE (progesterone gel), which is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 countries worldwide. The company was founded in December 1986 and is headquartered in Boston, MA.
|Frank C. Condella||President, Chief Executive Officer & Director|
|Nikin Patel||Chief Operating Officer & Director|
|George O. Elston||Chief Financial Officer, Secretary & Treasurer|
|Bridget A. Martell||Chief Medical Officer|
|Kip Martin||Vice President-Business Development|